Quantifying benefits and risks of vaccinating Australian children aged 6 months to 4 years with trivalent inactivated seasonal influenza vaccine in 2010

Australian and New Zealand health authorities identified seasonal trivalent inactivated influenza vaccines manufactured by CSL Biotherapies as the probable cause of increased febrile convulsions in children under five within 24 hours of vaccination and recommended against their use in this age group. We quantified the benefit-risk profile of the CSL vaccines using the number needed to vaccinate and suggest they might have caused two to three hospital admissions due to febrile convulsions for every hospital admission due to influenza prevented.

Read the full article
http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19661
Tweet